ArticleOncotarget2016

Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations.

Jianlin Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.